Form D · Other
Validus Cellular Therapeutics, Inc.
Aurora, CO · CIK 0001820379
Offering snapshot reported Jun 6, 2022 · SEC filing
- Reported sold
- $70K Offering amount: $500K
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 19, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 6, 2022 | Initial | $70,000 | No comparison | 5 | SEC filing |
| Jan 11, 2022 | Initial | $25,000 | No comparison | 1 | SEC filing |
| Aug 11, 2020 | Initial | $20,200 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-448181
Source: Form D, filed Jun 6, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Frank Barry | Director |
| Steven Dow | Director |
| Mike Handley | Director |
| Ethan Mann | Director, Executive |
Issuer details
Industry: Other (See others in industry)
Address:
12635 E Montview Blvd. Suite 100
Aurora, CO, 80045
Aurora, CO, 80045